Drug Pricing
Biosimilars
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Commentary
Congress should fulfill this drug program’s promise to vulnerable Californians
A federal program intended to help low-income patients has instead become a major revenue source for large California hospital systems. Hospitals are using gaps in oversight within the 340B Drug Pricing Program to lock in substantial margins on prescription drugs — and driving healthcare costs higher for Californians in the ...
Commentary
This Drug Patent Bill Would Hurt Innovation Without Lowering Prices
This week, the Senate Committee on Health, Education, Labor and Pensions will consider several bills that aim to “make health care more affordable and accessible to American families.” One in particular deserves a closer look. The Medication Affordability and Patent Integrity Act, introduced by Sen. Maggie Hassan, D-N.H., and co-sponsored ...
Commentary
Trump Should Stand Firm Against Europe’s Drug Price Free-Riders
For decades, wealthy foreign governments have left it to Americans to pay for pharmaceutical innovation — and then insisted on enjoying the fruits of that innovation at a discount. President Trump has begun challenging that status quo through trade negotiations designed to pressure foreign countries into paying more for innovative ...
Drug Innovation
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Commentary
Read the latest on drug innovation from Sally Pipes
Big Medical Breakthroughs Start With Small Gains
That may not sound like much. For someone facing a terminal diagnosis, what difference does a few extra months really make, especially if the drugs that enable them cost tens of thousands of dollars, as so many cancer drugs do? That question misses the point. In medicine, the most important ...
340B
It’s Time For Congress To Get 340B Out Of Its Blind Spot
That should alarm anyone concerned about rising healthcare costs, misuse of taxpayer dollars, financial burdens on employers, or the integrity of our nation’s safety net. Congress must stop ignoring this problem and inject some badly needed transparency into 340B. Read the full article at Forbes
Commentary
Trump Puts Drug Pricing Program Fraudsters on Notice
The Trump administration is ramping up its fight against waste, fraud, and abuse in healthcare. And that effort could help make care more affordable for millions of Americans. One of its latest targets is the 340B Drug Pricing Program, a little-known federal initiative that has warped the prescription drug market. ...
Commentary
Germany Wants Cheaper Drugs—And Americans To Pay The Difference
What does a new healthcare reform effort in Germany have to do with American patients? Quite a lot, actually. The German government is looking to cut healthcare spending by tens of billions of euros. To that end, it is pushing pharmaceutical companies to accept significantly lower prices for new medicines. ...
Commentary
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science. At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug. They are not arguing ...
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Congress should fulfill this drug program’s promise to vulnerable Californians
A federal program intended to help low-income patients has instead become a major revenue source for large California hospital systems. Hospitals are using gaps in oversight within the 340B Drug Pricing Program to lock in substantial margins on prescription drugs — and driving healthcare costs higher for Californians in the ...
This Drug Patent Bill Would Hurt Innovation Without Lowering Prices
This week, the Senate Committee on Health, Education, Labor and Pensions will consider several bills that aim to “make health care more affordable and accessible to American families.” One in particular deserves a closer look. The Medication Affordability and Patent Integrity Act, introduced by Sen. Maggie Hassan, D-N.H., and co-sponsored ...
Trump Should Stand Firm Against Europe’s Drug Price Free-Riders
For decades, wealthy foreign governments have left it to Americans to pay for pharmaceutical innovation — and then insisted on enjoying the fruits of that innovation at a discount. President Trump has begun challenging that status quo through trade negotiations designed to pressure foreign countries into paying more for innovative ...
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Read the latest on drug innovation from Sally Pipes
Big Medical Breakthroughs Start With Small Gains
That may not sound like much. For someone facing a terminal diagnosis, what difference does a few extra months really make, especially if the drugs that enable them cost tens of thousands of dollars, as so many cancer drugs do? That question misses the point. In medicine, the most important ...
It’s Time For Congress To Get 340B Out Of Its Blind Spot
That should alarm anyone concerned about rising healthcare costs, misuse of taxpayer dollars, financial burdens on employers, or the integrity of our nation’s safety net. Congress must stop ignoring this problem and inject some badly needed transparency into 340B. Read the full article at Forbes
Trump Puts Drug Pricing Program Fraudsters on Notice
The Trump administration is ramping up its fight against waste, fraud, and abuse in healthcare. And that effort could help make care more affordable for millions of Americans. One of its latest targets is the 340B Drug Pricing Program, a little-known federal initiative that has warped the prescription drug market. ...
Germany Wants Cheaper Drugs—And Americans To Pay The Difference
What does a new healthcare reform effort in Germany have to do with American patients? Quite a lot, actually. The German government is looking to cut healthcare spending by tens of billions of euros. To that end, it is pushing pharmaceutical companies to accept significantly lower prices for new medicines. ...
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science. At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug. They are not arguing ...